Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.48 USD | -1.40% | +3.41% | +44.67% |
May. 02 | Immunome, Inc. Appoints Kinney Horn as Chief Business Officer | CI |
Apr. 30 | JPMorgan Starts Immunome With Overweight Rating, $24 Price Target | MT |
Financials (USD)
Sales 2024 * | 9.6M | Sales 2025 * | 3.2M | Capitalization | 941M |
---|---|---|---|---|---|
Net income 2024 * | -104M | Net income 2025 * | -144M | EV / Sales 2024 * | 98 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 294 x |
P/E ratio 2024 * |
-8.57
x | P/E ratio 2025 * |
-6.89
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.97% |
1 day | -1.40% | ||
1 week | +3.41% | ||
Current month | +10.10% | ||
1 month | -24.41% | ||
3 months | -33.02% | ||
6 months | +80.84% | ||
Current year | +44.67% |
Managers | Title | Age | Since |
---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 23-10-01 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | 63 | 23-10-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | Jan. 01 |
Director/Board Member | 70 | Nov. 06 | |
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 15.48 | -1.40% | 344,517 |
24-05-08 | 15.7 | +2.41% | 505,028 |
24-05-07 | 15.33 | -0.84% | 342,932 |
24-05-06 | 15.46 | -1.84% | 492,494 |
24-05-03 | 15.75 | +5.21% | 729,276 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.67% | 928M | |
+2.97% | 108B | |
+10.21% | 104B | |
+1.57% | 22.33B | |
-12.77% | 22.19B | |
-7.05% | 18.69B | |
-37.64% | 17.74B | |
-6.50% | 17.64B | |
+6.00% | 14.05B | |
+37.20% | 12.51B |
- Stock Market
- Equities
- IMNM Stock